The blockage of FATP2 expression in MDSCs by lipofermata decreased lipid accumulation, decreased ROS, blocked immunosuppressive activity, lower PD-L1 expression on CD8+ TILs, and even enhanced anti-PD-L1 tumor immunotherapy. This evidence concerns the gene SLC27A2 and neoplasm.